
pmid: 6508458
To the Editor. —Stoudemire et al 1 eloquently described the difficult clinical problem of managing chemotherapy-induced emesis. Our experience with lorazepam suggests it is satisfactory for use even in regimens using cisplatin and in patients who previously suffered from anticipatory nausea and vomiting. 2 Lorazepam is a benzodiazepine with sedative, anxiolytic, and amnesic properties. We give it as a 4-mg dose, intramuscularly, two hours before treatment, then as 1 to 2 mg sublingually, hourly as needed, for up to six hours to maintain mild to moderate sedation, as defined by Gralla et al 3 ( mild : patient lethargic but aroused by verbal stimuli and completely oriented when awakened; moderate : patient aroused only by physical stimuli and completely oriented when awakened). Prochlorperazine is usually given rectally in a 25-mg dose at the beginning of treatment and four hours later if necessary. Our regimen resulted in adequate amnesia for emesis in 94% of
Vomiting, Humans, Lorazepam
Vomiting, Humans, Lorazepam
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 9 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
